Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GSK4418959

Small molecule · Inhibitor of Werner syndrome ATP-dependent helicase (WRN)

Phase 1/2 Most advanced trial
1 Registered trials

What is GSK4418959?

GSK4418959 is an orally bioavailable inhibitor of the Werner syndrome ATP-dependent helicase (WRN), a multifunctional enzyme with helicase and exonuclease activities involved in DNA replication and repair. It is being studied in solid tumors, including colorectal, colon, rectal and endometrial cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Werner syndrome ATP-dependent helicase (WRN)
Mechanism
Inhibitor of Werner syndrome ATP-dependent helicase (WRN)
Pathways
DNA replication, DNA repair
Therapy area
Oncology
In trials of
IDYA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06710847 Phase 1/2 Neoplasms, Colorectal Active not recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colon CancerEndometrial CancerNeoplasms, ColorectalRectal CancerSolid Tumor

Other drugs acting on WRN

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.